Literature DB >> 27837151

Atrial fibrillation, progression of coronary atherosclerosis and myocardial infarction.

Ozgur Bayturan1,2, Rishi Puri1,3, E Murat Tuzcu3, Mingyuan Shao1, Kathy Wolski1, Paul Schoenhagen3, Samir Kapadia3, Steven E Nissen1,3, Prashanthan Sanders4, Stephen J Nicholls4.   

Abstract

Background Despite atrial fibrillation representing an established risk factor for stroke, the association between atrial fibrillation and both progression of coronary atherosclerosis and major adverse cardiovascular events is not well characterized. We assessed the serial measures of coronary atheroma burden and cardiovascular outcomes in patients with and without atrial fibrillation. Methods Data were analyzed from nine clinical trials involving 4966 patients with coronary artery disease undergoing serial intravascular ultrasonography at 18-24 month intervals to assess changes in percent atheroma volume (PAV). Using a propensity weighted analysis, and following adjustment for baseline variables, patients with ( n = 190) or without ( n = 4776) atrial fibrillation were compared with regard to coronary plaque volume and major adverse cardiovascular events (death, myocardial infarction, and stroke). Results Atrial fibrillation patients demonstrated lower baseline PAV (36.0 ± 8.9 vs. 38.1 ± 8.9%, p = 0.002) and less PAV progression (-0.07 ± 0.34 vs. + 0.23 ± 0.34%, p = 0.001) compared with the non-atrial fibrillation group. Multivariable analysis revealed atrial fibrillation to independently predict both myocardial infarction [HR, 2.41 (1.74,3.35), p<0.001] 2.41 (1.74, 3.35), p < 0.00) and major adverse cardiovascular events [HR, 2.2, (1.66, 2.92), p<0.001] 2.20 (1.66, 2.92), p < 0.001]. Kaplan-Meier analysis showed that atrial fibrillation compared with non-atrial fibrillation patients had a significantly higher two-year cumulative incidence of overall major adverse cardiovascular events (4.4 vs. 2.0%, log-rank p = 0.02) and myocardial infarction (3.3 vs. 1.5%, log-rank p = 0.05). Conclusions The presence of atrial fibrillation independently associates with a heightened risk of myocardial infarction despite a lower baseline burden and progression rate of coronary atheroma. Further studies are necessary to define the pathogenesis of myocardial infarction in the setting of atrial fibrillation.

Entities:  

Keywords:  Intravascular ultrasound; atrial fibrillation; myocardial infarction

Mesh:

Year:  2016        PMID: 27837151     DOI: 10.1177/2047487316679265

Source DB:  PubMed          Journal:  Eur J Prev Cardiol        ISSN: 2047-4873            Impact factor:   7.804


  5 in total

Review 1.  Atrial fibrillation and the risk for myocardial infarction, all-cause mortality and heart failure: A systematic review and meta-analysis.

Authors:  Vidar Ruddox; Irene Sandven; John Munkhaugen; Julie Skattebu; Thor Edvardsen; Jan Erik Otterstad
Journal:  Eur J Prev Cardiol       Date:  2017-06-15       Impact factor: 7.804

2.  Atrial high‑rate episodes and risk of major adverse cardiovascular events in patients with dual chamber permanent pacemakers: a retrospective study.

Authors:  Wei-Da Lu; Ju-Yi Chen
Journal:  Sci Rep       Date:  2021-03-11       Impact factor: 4.379

3.  Development of atrial fibrillation following trauma increases short term risk of cardiovascular events.

Authors:  Sean P Nassoiy; Robert H Blackwell; McKenzie Brown; Anai N Kothari; Timothy P Plackett; Paul C Kuo; Joseph A Posluszny
Journal:  J Osteopath Med       Date:  2021-03-10

Review 4.  Physical activity types and atrial fibrillation risk in the middle-aged and elderly: The Rotterdam Study.

Authors:  Marijn Albrecht; Chantal M Koolhaas; Josje D Schoufour; Frank Ja van Rooij; M Kavousi; M Arfan Ikram; Oscar H Franco
Journal:  Eur J Prev Cardiol       Date:  2018-06-04       Impact factor: 7.804

5.  Characteristics and outcome of a first acute myocardial infarction in patients with ankylosing spondylitis.

Authors:  Anna Södergren; Johan Askling; Karin Bengtsson; Helena Forsblad-d'Elia; Tomas Jernberg; Ulf Lindström; Lotta Ljung; Ängla Mantel; Lennart T H Jacobsson
Journal:  Clin Rheumatol       Date:  2020-08-26       Impact factor: 2.980

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.